Cyberonics Inc. (CYBX) earnings estimates are rising since being featured as a Zacks Rank Buy in early December.

Company Description

Cyberonics Inc. develops and markets medical devices specifically focused on neurological disorders, including epilepsy, one of the most common neurological disorders. The company uses vagus nerve stimulation through its Cyberonics NCP System to reduce the severity and frequency of seizures.

Cyberonics distributes its products in North and South America, Asia, and Europe. The Houston-based medical products company has approximately 440 employees and a market cap. of $443 million.

Estimates Rising as Report Nears

Full-year consensus estimates for both fiscal 2009 and 2010 are up over the past 90 days. The average forecast for the current year is 47 cents, up from 32 cents, a 47% increase. Estimates for 2010 are now 66 cents, up from 54 cents over the same time period.

The company is set to report third-quarter results on Feb 18. If current expectations are met, year-over-year earnings growth till be 205% and 40% in 2009 and 2010, respectively.

Given an exceptional long-term growth rate of 35% over the next 5 years, shares are trading with a PEG ratio of 1.0.

The Chart

After forming a double bottom near $10 in October and November, shares of CYBX started to climb steadily. Take a look at the chart below.

Read the December 11th Feature Here

Last Week's Aggressive Growth Zacks Rank Buy Stocks

Apollo Group (APOL) has just crushed Wall Street estimates and shares are setting new multi-year highs. Read Full Article.

Corinthian Colleges Inc. (COCO) is rapidly approaching its earnings release and shares are showing bullish activity. Read Full Article.

Huron Consulting Group Inc. (HURN) is demonstrating excellent growth prospects in 2009 following a solid third-quarter earnings announcement. Read Full Article.

Biogen Idec Inc. (BIIB) shares continue to climb as the company's next earnings announcement quickly approaches. Biogen is looking for its fifth consecutive surprise on Feb 6. Read Full Article.
"CYBX" Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research

Company Description

Cyberonics Inc. develops and markets medical devices specifically focused on neurological disorders, including epilepsy, one of the most common neurological disorders. The company uses vagus nerve stimulation through its Cyberonics NCP System to reduce the severity and frequency of seizures.

Cyberonics distributes its products in North and South America, Asia, and Europe. The Houston-based medical products company has approximately 440 employees and a market cap. of $443 million.

A Strong Second Quarter

On Nov 19 Cyberonics released its second-quarter results which included a 24% increase in net sales. Sales where $36.0 million, up from $28.9 million. U.S. sales drove the higher numbers,

Given the excellent quarter, Cyberonics raised its sales guidance for fiscal 2009 to between $136 million and $140 million, up $2 million on the high and low end.

Net income was $8.3 million, turning the corner from its loss of $4.1 million one year ago. The net income figure equates to 14 cent per share, well above the 6 cents forecast by Wall Street.

Consistantly Surprising

The 133% second-quarter surprise was the fourth surprise this year, each averaging 164%.

Analysts continue to raise estimates after estimates for 2010 initial slid a few months ago. The current consensus for fiscal 2009 is 41 cents per share, up from 32 cents one month ago. Next years estimates are up to 59 cents from 54 cents over the same period of time.

The current consensus estimates are projecting year-over-year growth of 190% for fiscal 2009 and 45% for 2010. These rates are fairly priced with a PEG ratio of 1.1, right in line with the industry average.

The Chart

Shares of CYBX have successfully tested the 52-week low, forming a double bottom this fall. Since then, shares convincingly broke through resistance near $14. Take a look at the chart below.

"CYBX" Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research